IP Library › Assignment 031227/0227
Patent Assignment
Reel/Frame 031227/0227

Security Agreement

Recorded: 2013-09-18 Pages: 49
Assignor
WELLSTAT THERAPEUTICS CORPORATION
Executed: 2013-08-20
Assignee
PDL BIOPHARMA, INC.
932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE, NEVADA, 89451
Covered Properties (96)
Treatment of Chemotherapeutic Agent and Antiviral Agent Toxicity with Acylated Pyrimidine Nucleosides
Patent: 7,776,838 →
Application: 08/460,186 →
Inhibitor of Stem Cell Proliferation and Uses Thereof
Patent: 6,610,654 →
Application: 10/128,581 →
Publication: US 2003/0104984
Compounds for the Treatment of Metabolic Disorders
Patent: 7,101,910 →
Application: 10/167,839 →
Publication: US 2003/0149107
Pyrimidine Nucleotide Precursors for Treatment of Systemic Inflammation and Inflammatory Heptitis
Patent: 7,709,459 →
Application: 10/421,831 →
Publication: US 2003/0212036
Compounds for the Treatment of Metabolic Disorders
Patent: 7,329,782 →
Application: 10/481,042 →
Publication: US 2005/0256333
Compounds for the Treatment of Metabolic Disorders
Patent: 7,514,555 →
Application: 10/531,618 →
Publication: US 2006/0014784
Compounds for the Treatment of Metabolic Disorders
Patent: 7,615,575 →
Application: 10/531,630 →
Publication: US 2006/0247309
The Treatment of Metabolic Disorders
Patent: 7,645,772 →
Application: 10/532,690 →
Publication: US 2006/0035970
Compounds for the Treatment of Metabolic Disorders
Patent: 7,361,686 →
Application: 10/553,936 →
Publication: US 2007/0105955
Compounds for the Treatment of Metabolic Disorders
Patent: 7,442,796 →
Application: 10/554,586 →
Publication: US 2007/0173544
Compounds for the Treatment of Metabolic Disorders
Patent: 7,906,675 →
Application: 10/566,302 →
Publication: US 2007/0282003
Compounds for the Treatment of Metabolic Disorders
Patent: 6,924,314 →
Application: 10/684,644 →
Publication: US 2004/0077896
Compounds for the treatment of metabolic disorders
Patent: 6,858,602 →
Application: 10/684,660 →
Publication: US 2004/0236100
Compounds for the Treatment of Metabolic Disorders
Patent: 6,916,848 →
Application: 10/684,730 →
Publication: US 2004/0097585
Compounds for the Treatment of Metabolic Disorders
Patent: 7,041,659 →
Application: 10/684,735 →
Publication: US 2004/0092518
Compounds for the Treatment of Metabolic Disorders
Patent: 7,045,541 →
Application: 10/684,740 →
Publication: US 2004/0267025
Compounds for the Treatment of Metabolic Disorders
Patent: 6,946,491 →
Application: 10/685,183 →
Publication: US 2004/0092516
Compounds for the Treatment of Metabolic Disorders
Application: 10/865,088 →
Publication: US 2004/0242692
Compounds for the Treatment of Metabolic Disorders
Patent: 7,012,071 →
Application: 10/892,950 →
Publication: US 2005/0004115
Inhibitor of stem cell proliferation and uses thereof
Application: 10/897,005 →
Publication: US 2005/0043218
Compound for the treatment of metabolic disorders
Patent: 8,487,000 →
Application: 11/005,449 →
Publication: US 2005/0090555
Methods for the Treatment of Metabolic Disorders Such as Diabetes
Patent: 8,552,062 →
Application: 11/535,779 →
Publication: US 2007/0105958
Compounds for the Treatment of Metabolic Disorders
Application: 11/772,501 →
Publication: US 2007/0249696
Method for the Treatment of Metabolic Disorders
Patent: 7,851,494 →
Application: 11/772,504 →
Publication: US 2007/0265322
Method for the Treatment of Metabolic Disorders
Application: 11/772,511 →
Publication: US 2007/0249719
Method for the Treatment of Metabolic Disorders
Application: 11/772,515 →
Publication: US 2007/0244171
Method for the Treatment of Metabolic Disorders
Application: 11/772,520 →
Publication: US 2007/0244141
Method for the Treatment of Metabolic Disorders
Application: 11/772,556 →
Publication: US 2007/0265323
Method for the Treatment of Metabolic Disorders
Patent: 8,604,083 →
Application: 11/772,560 →
Publication: US 2007/0244172
Method for the Treatment of Metabolic Disorders
Patent: 7,605,181 →
Application: 11/841,489 →
Publication: US 2008/0015254
Compounds for the Treatment of Metabolic Disorders
Application: 11/841,508 →
Publication: US 2008/0015209
Compounds for the Treatment of Metabolic Disorders
Patent: 7,547,802 →
Application: 11/844,431 →
Publication: US 2008/0021109
Compounds for the Treatment of Metabolic Disorders
Patent: 7,863,475 →
Application: 11/844,432 →
Publication: US 2008/0027229
Access Control to Partitioned Blocks in Shared Memory
Application: 11/909,121 →
Publication: US 2009/0254713
Compounds for the Treatment of Metabolic Disorders
Patent: 8,178,675 →
Application: 12/092,932 →
Publication: US 2009/0203793
Compounds for the Treatment of Metabolic Disorders
Patent: 7,820,721 →
Application: 12/160,854 →
Publication: US 2008/0306165
Compounds for the Treatment of Metabolic Disorders
Patent: 7,915,429 →
Application: 12/160,857 →
Publication: US 2008/0319049
Compounds for the Treatment of Metabolic Disorders
Patent: 7,947,735 →
Application: 12/160,858 →
Publication: US 2008/0306150
Compounds for the Treatment of Metabolic Disorders
Application: 12/162,397 →
Publication: US 2009/0176885
Compositions for the Treatment of Metabolic Disorders
Patent: 7,749,990 →
Application: 12/208,877 →
Publication: US 2009/0005451
Compounds for the Treatment of Metabolic Disorders
Patent: 8,044,243 →
Application: 12/279,247 →
Publication: US 2009/0176889
Compounds for the Treatment of Metabolic Disorders
Application: 12/279,808 →
Publication: US 2010/0227901
Combination Treatment of Metabolic Disorders
Patent: 8,338,480 →
Application: 12/294,530 →
Publication: US 2010/0292277
Compounds for the Treatment of Metabolic Disorders
Patent: 7,935,689 →
Application: 12/300,239 →
Publication: US 2009/0163576
Compounds for the Treatment of Metabolic Disorders
Application: 12/304,007 →
Publication: US 2010/0234464
Combination Treatment for Metabolic Disorders
Application: 12/377,460 →
Publication: US 2010/0227809
Compounds for the Treatment of Metabolic Disorders
Patent: 7,973,052 →
Application: 12/392,675 →
Publication: US 2009/0156681
Hemoglobin Alpha Chain Peptide Fragments Useful for Inhibiting Stem Cell Proliferation
Application: 12/534,675 →
Publication: US 2010/0041147
Method for the Treatment of Metabolic Disorders
Patent: 7,932,290 →
Application: 12/550,482 →
Publication: US 2010/0087541
Compounds for the Treatment of Metabolic Disorders
Patent: 8,481,595 →
Application: 12/812,514 →
Publication: US 2010/0286267
Compounds and Method for Reducing Uric Acid
Patent: 8,829,058 →
Application: 12/920,555 →
Publication: US 2011/0014176
Tetrazole Compounds for Reducing Uric Acid
Patent: 8,410,154 →
Application: 12/989,724 →
Publication: US 2011/0206653
Synthesis of 4-[3-(2,6-Dimethylbenzyloxy)Phenyl]-4-Oxobutanoic Acid
Patent: 8,664,433 →
Application: 12/990,851 →
Publication: US 2011/0201838
Compounds for the Treatment of Metabolic Disorders
Application: 13/034,201 →
Publication: US 2011/0166233
Synthesis of (Phenylalkyloxy)Phenyl-Oxobutanoic Acids
Patent: 8,703,991 →
Application: 13/127,120 →
Publication: US 2012/0004442
Compounds for the Treatment of Metabolic Disorders
Application: 13/217,977 →
Publication: US 2012/0071526
Determining the Severity of 5-Fluorouracil Overdose
Application: 13/319,563 →
Publication: US 2012/0078529
3-Substituted Compounds for Reducing Uric Acid
Patent: 8,546,448 →
Application: 13/501,338 →
Publication: US 2012/0201803
Combination Treatment for Metabolic Disorders
Application: 13/749,135 →
Publication: US 2013/0137629
Tetrazole Compounds for Reducing Uric Acid
Patent: 8,889,724 →
Application: 13/783,680 →
Publication: US 2013/0336949
Benzoic Acid Compounds for Reducing Uric Acid
Application: 13/821,402 →
Publication: US 2013/0331452
Compounds for the treatment of metabolic disorders
Application: 60/297,282 →
Compounds for the treatment of metabolic disorders
Application: 60/423,253 →
Compounds for the treatment of metabolic disorders
Application: 60/447,168 →
Compounds for the treatment of metabolic disorders
Application: 60/462,960 →
Compounds for the treatment of metabolic disorders
Application: 60/464,553 →
Compounds for the treatment of metabolic disorders
Application: 60/466,663 →
Compounds for the treatment of metabolic disorders
Application: 60/496,533 →
Compounds for the treatment of metabolic disorders
Application: 60/667,457 →
Compounds for the treatment of metabolic disorders
Application: 60/734,803 →
Combination Treatment of Metabolic Disorders
Application: 60/744,021 →
Compounds for the Treatment of Metabolic Diseases
Application: 60/747,638 →
Compounds for the treatment of metabolic disorders
Application: 60/762,066 →
Compounds for the treatment of metabolic disorders
Application: 60/762,068 →
Compounds for the treatment of metabolic disorders
Application: 60/762,091 →
Compounds for the treatment of metabolic disorders
Application: 60/764,544 →
Compounds for the treatment of metabolic disorders
Application: 60/772,687 →
Compounds for the treatment of metabolic disorders
Application: 60/777,678 →
Compounds for the Treatment of Metabolic Disorders
Application: 60/804,336 →
Combination Treatment for Metabolic Disorders
Application: 60/822,676 →
Compounds for the Treatment of Metabolic Disorders
Application: 61/021,061 →
Compounds and Method for Reducing Uric Acid
Application: 61/036,294 →
Tetrazole Compounds for Reducing Uric Acid
Application: 61/049,167 →
Synthesis of 4-[3-(2,6-Dimethylbenzyloxy)Phenyl]-4-Oxobutanoic Acid
Application: 61/050,442 →
Synthesis of 4-[3-(2,6-Dimethylbenzyloxy)Phenyl]-4-Oxobutanoic Acid
Application: 61/057,410 →
Tetrazole Compounds for Reducing Uric Acid
Application: 61/093,743 →
Compounds for the Treatment of Metabolic Disorders
Application: 61/096,576 →
Synthesis of (Phenylalkyloxy)Phenyl-Oxobutanoic Acids
Application: 61/111,133 →
Determining the Severity of 5-Fluorouracil Overdose
Application: 61/177,890 →
3-Substituted Compounds for Reducing Uric Acid
Application: 61/251,098 →
Benzoic Acid Compounds for Reducing Uric Acid
Application: 61/380,882 →
3-Benzyloxyphenyloxoacetic Acid Compounds for Reducing Uric Acid
Application: 61/452,410 →
Stem Cell Mobilization and Tissue Regeneration
Application: 61/487,548 →
Stem Cell Mobilization and Tissue Repair and Regeneration
Application: 61/728,058 →
Stem Cell Mobilization and Tissue Repair and Regeneration
Application: 61/735,227 →
Amine Compounds Having Antiparasitic Activity
Application: 61/759,512 →
Related Assignments (10)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Aug 19, 2002
From: SHARMA, SHALINI; VON BORSTEL, REID W.; HODGE, KIRVIN L.
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 013219/0513 →
Assignment of Assignor's Interest Jun 18, 2003
From: TSYRLOVA, IRENA; WOLPE, STEPHEN D.
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 014187/0730 →
Assignment of Assignor's Interest Dec 12, 2003
From: SHARMA, SHALINI; VON BORSTEL, REID W.; HODGE, KIRVIN L.; BAMAT, MICHAEL K.
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 015534/0374 →
Assignment of Assignor's Interest Mar 21, 2006
From: VENTURE MANAGEMENT ALLIANCE LLC
To: CDC INVESTMENTS, LLLP
Reel/Frame 017707/0189 →
Security Agreement Aug 16, 2013
From: WELLSTAT THERAPEUTICS CORPORATION
To: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031029/0875 →
Release of Security Interest Jan 21, 2021
From: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 055056/0891 →
Release of Certain Intellectual Property Collateral Owned by Wellstat Therapeutics Corporation Recorded at Reel 031227/Frame 0227 Jun 30, 2023
From: PDL BIOPHARMA, INC.
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 064180/0456 →
Assignment of Assignor's Interest Nov 6, 2023
From: WELLSTAT THERAPEUTICS CORPORATION
To: PHARMA CINQ, LLC
Reel/Frame 065474/0475 →
Assignment of Assignor's Interest Apr 20, 2024
From: WELLSTAT THERAPEUTICS CORPORATION
To: PHARMA CINQ, LLC
Reel/Frame 067173/0027 →
Assignment of Assignor's Interest Oct 30, 2024
From: WELLSTAT THERAPEUTICS CORPORATION
To: BTG INTERNATIONAL INC.
Reel/Frame 069079/0028 →